Plasma fibroblast growth factor 23 concentration is increased and predicts mortality in patients on the liver-transplant waiting list

PLoS One. 2013 Jun 25;8(6):e66182. doi: 10.1371/journal.pone.0066182. Print 2013.

Abstract

High plasma fibroblast growth factor-23 (FGF23) concentration predicts the risk of death and poor outcomes in patients with chronic kidney disease or chronic heart failure. We checked if FGF23 concentration could be modified in patients with end stage liver disease (ESLD) and predict mortality. We measured plasma FGF23 in 200 patients with ESLD registered on a liver transplant waiting list between January 2005 and October 2008. We found that median plasma FGF23 concentration was above normal values in 63% of the patients. Increased FGF23 concentration was not explained by its classical determinants: hyperphosphataemia, increased calcitriol concentration or decreased renal function. FGF23 concentration correlated with the MELD score, serum sodium concentration, and GFR. Forty-six patients died before being transplanted and 135 underwent liver transplantation. We analyzed the prognostic value of FGF23 levels. Mortality was significantly associated with FGF23 levels, the MELD score, serum sodium concentration and glomerular filtration rate. On multivariate analyses only FGF23 concentration was associated with mortality. FGF23 levels were independent of the cause of the liver disease. To determine if the damaged liver can produce FGF23 we measured plasma FGF23 concentration and liver FGF23 mRNA expression in control and diethyl-nitrosamine (DEN)-treated mice. FGF23 plasma levels increased with the apparition of liver lesions in DEN-treated mice and that FGF23 mRNA expression, which was undetectable in the liver of control mice, markedly increased with the development of liver lesions. The correlation between FGF23 plasma concentration and FGF23 mRNA expression in DEN-treated mice suggests that FGF23 production by the liver accounts for the increased plasma FGF23 concentration. In conclusion chronic liver lesions can induce expression of FGF23 mRNA leading to increased FGF23 concentration, which is associated with a higher mortality in patients on a liver-transplant waiting list. In these patients FGF23 concentration was the best predictor of mortality.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Female
  • Fibroblast Growth Factors / blood*
  • Humans
  • Liver Diseases / blood
  • Liver Diseases / mortality
  • Liver Transplantation*
  • Male
  • Middle Aged
  • Waiting Lists
  • Young Adult

Substances

  • Fibroblast Growth Factors
  • fibroblast growth factor 23

Grant support

This work was supported by grants from INSERM, Université Paris Descartes, Association Laboratoire de Recherches Physiologiques, and l’Agence Nationale pour la Recherche (ANR-07-PHYSIO-017-01). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.